Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Boyer

Showing results (51-60 of 1,264) with videos related to

Pageof 127
Sort By:
Radiation Research|February 1, 1988
Relationship between attenuation coefficients and dose-spread kernelsA L Boyer
Hepatology (Baltimore, Md.)|March 7, 2001
Advancing the bile-ology of cholestatic liver diseaseJ L Boyer
Gastroenterology|June 1, 1978
Mechanisms of chlorpromazine cholestasis: hypersensitivity or toxic metabolite?J L Boyer
Mondes En Developpement|January 1, 1984
[Demographic dimensions of the world economic crisis]P L Boyer
American Journal of Clinical Pathology|May 1, 1976
The diagnosis and pathogenesis of clinical variants in viral hepatitisJ L Boyer
Journal of Hepatology|January 16, 2007
New perspectives for the treatment of cholestasis: lessons from basic science applied clinicallyJames L Boyer
Hepatology (Baltimore, Md.)|February 27, 2009
It's all about bileJames L Boyer
Gastroenterology|August 9, 2005
Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease?James L Boyer
Gastroenterology|July 1, 1988
Definitive therapy for primary biliary cirrhosis--fact or fiction?J L Boyer
Clinical Liver Disease|May 2, 2019
Treatment of chronic cholestasis: What we know and what we will know?James L Boyer
Pageof 127

Showing results (51-60 of 1,264) with videos related to

Sort By:
Pageof 127
Radiation Research|February 1, 1988
Relationship between attenuation coefficients and dose-spread kernelsA L Boyer
Hepatology (Baltimore, Md.)|March 7, 2001
Advancing the bile-ology of cholestatic liver diseaseJ L Boyer
Gastroenterology|June 1, 1978
Mechanisms of chlorpromazine cholestasis: hypersensitivity or toxic metabolite?J L Boyer
Mondes En Developpement|January 1, 1984
[Demographic dimensions of the world economic crisis]P L Boyer
American Journal of Clinical Pathology|May 1, 1976
The diagnosis and pathogenesis of clinical variants in viral hepatitisJ L Boyer
Journal of Hepatology|January 16, 2007
New perspectives for the treatment of cholestasis: lessons from basic science applied clinicallyJames L Boyer
Hepatology (Baltimore, Md.)|February 27, 2009
It's all about bileJames L Boyer
Gastroenterology|August 9, 2005
Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease?James L Boyer
Gastroenterology|July 1, 1988
Definitive therapy for primary biliary cirrhosis--fact or fiction?J L Boyer
Clinical Liver Disease|May 2, 2019
Treatment of chronic cholestasis: What we know and what we will know?James L Boyer
Pageof 127